 Nes Ziona, Israel, Feb. 09, 2021 GLOBE NEWSWIRE -- Enlivex Therapeutics Ltd. NASDAQ: ENLV, a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that it has entered into an underwriting agreement with H.C. Wainwright Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 500,000 ordinary shares, par value NIS 0.40 per share, of the Company at a price to the public of 20.00 per ordinary share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 12, 2021, subject to satisfaction of customary closing conditions. 